THERMO FISHER SCIENTIFIC INC（TMO）の決算・業績分析
THERMO FISHER SCIENTIFIC INCの2025年有価証券報告書をAI分析。売上高$44.6B(+3.9%)。営業利益$7.7B。Health Care。
目次
THERMO FISHER SCIENTIFIC INCの2025年度 業績サマリー
THERMO FISHER SCIENTIFIC INC（証券コード: TMO）の2025年度決算・業績分析。売上高は$44.6B（前年比+3.9%）。営業利益は$7.7B（前年比+5.6%）。純利益は$6.7B（前年比+5.8%）。有価証券報告書を基に、業績変化の要因・リスク・見通し・セグメント構成を AI が分析しました。
THERMO FISHER SCIENTIFIC INCの2024年度 注目ポイント
※ 直近の2025年度XBRLデータは取込済みですが、AI分析は2024年度の10-Kを対象としています。
- Revenue increased 14.5% YoY to $44.9B (XBRL), but operating income declined 16.3% YoY to $8.4B (XBRL).
- Net income fell 9.9% YoY to $7.0B (XBRL), while free cash flow remained strong at $6.9B (XBRL).
- Net debt rose to $26.6B (2.8x EBITDA) (XBRL), reflecting continued capital expenditures and share repurchases.
- Cash conversion cycle (CCC) was 85 days (XBRL), driven by 67-day receivables and 41-day inventory.
THERMO FISHER SCIENTIFIC INCの売上高変化の要因
- •Total revenue grew 14.5% YoY to $44.9B (XBRL), driven by growth in Analytical Instruments, Specialty Diagnostics, and Laboratory Products segments. However, Life Sciences Solutions declined due to reduced demand for pandemic-related products. Historical revenue increased from $24.4B (2020) to $44.9B (2024), though 2025 projections show a slight decline to $42.9B (XBRL). Macroeconomic weakness in China and lower pandemic-related demand offset growth in other segments.
THERMO FISHER SCIENTIFIC INCの営業利益変化の要因
- •Operating income fell 16.3% YoY to $8.4B (XBRL), with a margin of 18.7% (vs. prior years). Net income declined 9.9% YoY to $7.0B (XBRL), with a net margin of 15.5%. EBITDA remained robust at $9.4B (20.9% margin). Declines in operating income were attributed to unfavorable business mix, strategic investments, and reduced pandemic-related demand, partially offset by lower amortization (10-K).
THERMO FISHER SCIENTIFIC INCの事業リスクと対応
Economic downturns and inflation could reduce demand, increase costs, and disrupt operations (10-K).
Currency fluctuations (e.g., $0.08B unfavorable revenue impact in 2024) and geopolitical instability pose risks (10-K).
Supply chain disruptions from tariffs, pandemics, or geopolitical events may harm production and logistics (10-K).
Reliance on customer capital spending and government funding policies affects product demand (10-K).
Regulatory challenges, including data privacy laws and trade barriers, increase compliance complexity (10-K).
THERMO FISHER SCIENTIFIC INCの今後の見通し・業績予想
THERMO FISHER SCIENTIFIC INCの事業内容
Thermo Fisher Scientific Inc. (TMO) enables healthier, cleaner, and safer environments through innovative technologies, purchasing convenience, and pharmaceutical services. The company operates four segments: Life Sciences Solutions (reagents, instruments for research and drug production), Analytical Instruments (chromatography, mass spectrometry), Specialty Diagnostics (diagnostic test kits), and Laboratory Products and Biopharma Services (lab supplies, biopharma manufacturing). Key customers include pharmaceutical firms, hospitals, academic institutions, and government agencies. Competitive advantages include $1.5B in R&D investment (XBRL) and global distribution networks.
THERMO FISHER SCIENTIFIC INCのAI業績分析レポート（2024年度）
Annual Report Analysis: Thermo Fisher Scientific Inc. (TMO) FY2024
Highlights
Business Overview
Thermo Fisher Scientific Inc. (TMO) operates four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The company generates revenue by selling reagents, instruments, consumables, and services to pharmaceutical, biotech, healthcare, academic, and government markets. Competitive advantages include $1.5B in R&D investment (XBRL) and global distribution networks.
Revenue Analysis
Total revenue grew 14.5% YoY to $44.9B (XBRL), driven by growth in Analytical Instruments, Specialty Diagnostics, and Laboratory Products segments. However, Life Sciences Solutions declined due to reduced demand for pandemic-related products. Historical revenue increased from $24.4B (2020) to $44.9B (2024), though 2025 projections show a slight decline to $42.9B (XBRL). Macroeconomic weakness in China and lower pandemic-related demand offset growth in other segments.
Profitability Analysis
Operating income fell 16.3% YoY to $8.4B (XBRL), with a margin of 18.7% (vs. prior years). Net income declined 9.9% YoY to $7.0B (XBRL), with a net margin of 15.5%. EBITDA remained robust at $9.4B (20.9% margin). Declines in operating income were attributed to unfavorable business mix, strategic investments, and reduced pandemic-related demand, partially offset by lower amortization (10-K).
Balance Sheet Analysis
Total assets rose to $97.2B (XBRL), with total equity increasing to $46.7B (XBRL). Liquidity remains strong with $8.1B in cash (XBRL). Net debt of $26.6B (2.8x EBITDA) (XBRL) reflects capital expenditures and share repurchases. Current ratio is 1.75x (XBRL), and equity ratio is 48.1% (XBRL).
Cash Flow Analysis
Operating cash flow was $9.2B (XBRL), with free cash flow of $6.9B (XBRL) after $2.2B in CapEx (XBRL). Shareholder returns totaled $3.5B, including $455M in dividends (XBRL) and $3.0B in share repurchases (XBRL). Investing cash flow was -$2.2B (XBRL), and financing cash flow was -$2.8B (XBRL).
Working Capital Analysis
Cash conversion cycle (CCC) was 85 days (XBRL), with 67-day receivables, 41-day inventory, and 23-day payables.
Risks
Outlook
Management expects a muted macroeconomic environment, reduced demand for pandemic-related products, and ongoing investments in innovation and commercial capabilities to impact future results (10-K). No specific guidance was provided for FY2025.
Health Careの企業一覧
THERMO FISHER SCIENTIFIC INCと同じ「Health Care」セクターの企業